Adalvo announces the restart of the DCP procedure for Desogestrel/Ethinylestradiol 150/20 micrograms film-coated tablets, with an anticipated EU approval date for August 2024.
Developed based on the reference brand Mercilon film-coated tablets, Desogestrel/Ethinylestradiol is a low-dose contraceptive used by women to prevent pregnancy.
According to IQVIA, Desogestrel+Ethinylestradiol (0.15mg+0.02mg) generated approximately $80mn in global sales, in 2023.
The development of Desogestrel/Ethinylestradiol showcases Adalvo's capability to host a diverse and comprehensive women's health portfolio.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now!